欢迎来到泽塔制药
泽溚制药是一家快速发展的埃及公司，成立于2010年，旨在代表制药行业的附加值。
泽塔制药在所有治疗领域都有精心挑选的独特产品组合。
泽制药已于2015年开始其丙型肝炎病毒（索非布韦、泽塔西弗和索磷布韦）产品的营销活动
泽塔制药与埃及卫生部和埃及肝脏研究所合作，成功治疗了60000多名患者，治愈率95%，与全球治愈率相似。
我们的使命与愿景
Our Vision
Our Mission
泽塔历史
Cool Timeline
2022 launched New 9 Products
1-Nexirozova Launch:
Jan – 2022, Zeta Pharma launched Nexirozova; a new generic of the anti-dyslipidemic molecule Rosuvastatin 5,10,20mg,
2021 Launched New 7 Products
1- Bilastegic Launch:
Jan – 2021, Zeta Pharma launched its new product, Bilastegic the world’s latest and most effective product for allergic diseases,
EBRD Agreement 2020
The European Bank for Reconstruction and Development (EBRD) is providing consultancy studies to Zeta Pharma factory in Egypt to qualify for European GMP accreditation.
2020 Launched New 4 Products
1- Empacoza Lunch:
Zeta Pharma launches “Empacoza” type 2 diabetes medicine in the Egyptian Market, In presence of famous Egyptian professors of Internal medication and endocrinology,
2019 Launched New 5 Products
1- Ancavaz Launch:
Zeta launched Ancavaz -which is indicated as a substitution therapy for the treatment of hypertension and/or stable coronary heart disease,
2018 Launched 4 New Products
1- Nexicure Launch:
12/10/2018
Zeta launched Nexicure Esomeprazole 20/40 mg MUPS tablet,
100 Millions Seha
Interview with Major General Mahmoud Ashmawi, Governor of Qalyubia governorate, and Dr. Hamdi El Tabakh, the Ministry of Health representative in Qalyubia in the launch of the Hepatitis C eradication campaign,
HCV Launch
Zeta Pharma Has started its marketing activities in 2015 on the products for Hepatitis C Virus (Sofocivir, Zetaciver & Sofocivir Plus).
